The medicine Nobel rewards a way to switch brain cells on with light. Here is how optogenetics works

The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics,” the Nobel Assembly at Karolinska Institutet in Stockholm announced on October 5. Deisseroth works at Stanford University, Hegemann at Humboldt University in Berlin and Nagel at the University of Würzburg. The three share the prize equally.

Optogenetics is a method for controlling chosen nerve cells with light. Researchers insert a gene that makes a light-sensitive protein, aim light at the tissue, and the cells that carry the protein respond while their neighbors do not. In the two decades since it was first shown to work in neurons, it has become a standard laboratory technique for working out which cells drive which behaviors. The prize recognizes both halves of that story: the discovery of the protein in an alga, and the demonstration that it could be used as a switch in nerve cells.

Start with an alga that swims toward light

The work began far from the brain. Hegemann wanted to understand how Chlamydomonas, a single-celled green alga, steers toward light. Accounts of the timeline differ slightly: STAT traces the start of the effort to the early 1990s, while the Nobel committee’s summary places the key discoveries in the early 2000s. The answer lay in proteins in the alga’s light-sensing spot that act as channels. When light strikes them, they open and let charged particles flow across the cell membrane.

Hegemann and Nagel identified these proteins, now called channelrhodopsins. According to the Nobel committee’s popular-information summary, they published results in 2003 and proposed that one of them, channelrhodopsin-2, could be a powerful tool for triggering electrical impulses with light in other kinds of cells.

That idea matters because of how nerve cells communicate. A neuron fires when the electrical charge across its membrane shifts past a threshold, and that shift happens when ion channels open and charged particles rush in. Most ion channels in the body open in response to chemical signals or changes in voltage. A channel that opens in response to light offered a different kind of handle: if it could be placed in a neuron, a beam of light could make that neuron fire.

Turning a protein into a switch

Deisseroth supplied the demonstration. The Nobel press release says he published the breakthrough in 2005: he introduced the gene for channelrhodopsin into nerve cells from rats and triggered nerve signals by illuminating them with blue light. The cells that had taken up the gene responded on cue. Cells without it did not.

Two features made the result useful rather than merely clever. First, genes can be delivered to specific types of cells, so researchers could choose which population of neurons became light-sensitive. Second, light can be switched on and off in milliseconds, which is roughly the timescale on which neurons signal. Earlier ways of stimulating the brain, such as electrodes or drugs, tended to affect everything nearby or acted far more slowly.

Coverage of the prize has described the result as a way to switch individual nerve cells on, or off, inside a living brain. Related light-sensitive proteins can be used to quiet cells rather than excite them, so the same approach allows researchers to test what happens when a group of neurons is silenced.

What it changed in neuroscience

Before optogenetics, much of what scientists knew about brain circuits came from recording activity and looking for correlations. A group of cells might become active when an animal felt fear, for example, but that did not prove the cells caused the fear. With a light switch for specific neurons, researchers could activate or silence a circuit and watch the effect directly.

That shift from correlation to cause is the reason the method spread so widely. It is now used to study movement, memory, sleep, appetite, reward and the circuits involved in conditions such as depression and addiction, mostly in animal models. The prize citation does not claim cures; it recognizes a discovery that changed how a whole field asks questions.

It also illustrates a pattern the Nobel committees often reward: basic research with no obvious application producing a general-purpose tool. Studying how an alga moves toward the sun was not a medical project. The tool it produced is now used widely in laboratories around the world.

Where it is reaching patients

Using optogenetics in people is harder than using it in laboratory animals. It requires gene therapy to deliver the light-sensitive protein, a way to get light to the target tissue, and evidence that the protein is safe in human cells over time. The eye is the most accessible starting point, because light already reaches the retina.

In retinitis pigmentosa, an inherited disease, the light-sensing photoreceptor cells of the retina die, but other retinal cells often survive. Optogenetic approaches try to make those surviving cells, such as retinal ganglion cells, respond to light directly, bypassing the lost photoreceptors. Because the approach does not depend on repairing a particular faulty gene, it could in principle help patients regardless of which mutation caused their disease.

A first-in-human study reported in 2021 showed partial recovery of visual function in a blind patient with retinitis pigmentosa. More recently, the University of Pittsburgh Medical Center announced results published in the New England Journal of Medicine in which an optogenetics-based treatment was safely given to 10 patients and improved visual function in some of them when used with a specially designed visual stimulation device worn as goggles. Other programs, including one from the company Nanoscope, are in later-stage trials.

Those results are early. The improvements reported so far are partial, the trials are small, and longer follow-up is needed to establish durability and safety. Readers should treat optogenetic therapy as a promising field under study, not an available treatment.

What to take from this year’s prize

For non-specialists, the useful point is how the method works rather than any single finding it produced. Optogenetics combines three things: a protein borrowed from nature, gene delivery to put it in chosen cells, and light to control those cells precisely in time. Each piece existed in some form before; the laureates’ contribution was showing that the protein existed, that it could work in other cells, and that it could control neurons in a living system.

The prize also arrives as neuroscience leans heavily on such tools to map circuits in detail. Optogenetics is often paired with imaging methods that show which cells are active, so researchers can both watch and manipulate the same circuit. That pairing underpins much of modern systems neuroscience.

The prize money is 12 million Swedish kronor, divided equally. The laureates will receive their awards at the ceremony in Stockholm on December 10.